Summary
The Momentum Growth Quotient for the company is 13.45, which is 27.52% higher than the average for the S&P 100.
Shares present a forward rate of return of 23.40% at the current price.
The company's recently launched DNA Body Blueprint program gives it a competitive edge and should help it gain market share in the weight-loss market.
ChartMasterPro upward target price of $43.00.
Target return for my options trade is 85%.
Shares of Nutrisystem Inc. (NTRI) are down 15.93% since peaking on August 3, 2018, and in my opinion, the shares of this provider of weight management products and services are an attractive buy at current price levels. The company has a solid history of generating outstanding earnings growth, and the future growth ratios point to continued growth over the next twelve months. I lay out my bullish argument for the company below by reviewing some pertinent fundamental and technical aspects of the stock.
